Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Core Insights - Bone Biologics Corporation has successfully extended the shelf life of its rhNELL-1 product to 24 months, aligning with previous forecasts [1][2] - This extension is supported by ongoing stability data and marks a progression from earlier validated shelf-life milestones of 12 and 18 months [2] - The extended shelf life is anticipated to improve manufacturing efficiency, inventory management, supply-chain flexibility, and overall clinical and commercial readiness as the company advances rhNELL-1 through development [2][3] Company Development - The achievement of a 24-month shelf life is viewed as a significant step toward commercialization, enhancing operational capabilities and supporting disciplined capital deployment for long-term shareholder value creation [3] - Bone Biologics is focused on developing rhNELL-1 as a differentiated bone growth factor aimed at promoting controlled bone regeneration, particularly in challenging fusion settings [3][4] - The company is collaborating with strategic partners to leverage preclinical research on the NELL-1 protein, with a focus on spinal fusion procedures and potential applications in trauma and osteoporosis [4]